Hint mode is switched on Switch off
For swift navigation between sections

Chimerix

PDF download

Choose all Reset all
Download Cancel
Organization name
Chimerix, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Get access Watch full tour

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Awards

News

21/04/2025 Chimerix: Termination Of A Material Definitive Agreement, Completion Of Acquisition Or Disposition Of Assets, Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing, Material Modification To Rights Of Security Holders, Changes In Control Of Registrant, Departure Of Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year, Financial Statements And Exhibits
21/03/2025 Chimerix: Results Of Operations And Financial Condition, Financial Statements And Exhibits
12/03/2025 Chimerix, Inc. (NASDAQ: CMRX) Overview: A Biopharmaceutical Innovator on the Verge of a Breakthrough
04/03/2025 Chimerix: Of This Report, Including Exhibit 99.1 Attached Hereto, Is Furnished Pursuant To Item 7.01 Of Form8kand Shall Not Be Deemed “filed” For Purposes Of Section18 Of The Securities Exchange Act Of 1934, As Amended, Or Subject To The Liabilities Of That Section. The Information Shall Not Be Deemed Incorporated By Reference Into Any Other Filing With The Sec Made By The Company Regardless Of Any General Incorporation Language In Such Filing, Except As Shall Be Expressly Set Forth By Specific Reference In Such Filing
04/03/2025 Chimerix: Of The Original Report Are Incorporated Into This Amended Report By Reference Without Changes, Except That All References To Exhibit 2.1 In The Original Report Refer To Exhibit 2.1 Filed Herewith
All organization news

Documentation

IFRS/US GAAP reports

2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001117480
  • EIN
    33-0903395
Registration is required to get access.